药物涂层球囊与新一代药物洗脱支架治疗冠脉支架内再狭窄临床疗效对比研究

Comparative Study of Clinical Efficacy of Drug-coated Balloon and New-generation Drug-eluting Stent in Treating Coronary Restenosis

目的对比药物涂层球囊与新一代药物洗脱支架治疗冠脉支架内再狭窄临床疗效。方法方便选取该院的60例冠脉支架内再狭窄病患作为该次的研究对象,患者纳入时间为2018年2月-2019年6月,采用数字随机法对患者进行分组,一组应用药物涂层球囊进行治疗,一组应用新一代药物洗脱支架治疗,分别作为对照组和研究组,对比两组患者治疗后的脂代谢情况、不良事件和再次狭窄发生率、治疗满意度。结果研究组患者干预后BMI为(20.31±1.31)kg/m^2,SBP为(122.31±4.22)mmHg,DBP为(87.83±4.22)mmHg,TC为(3.42±0.33)mmol/L,TG为(1.56±0.62)mmol/L,HDL-C为(1.81±0.28)mmol/L,LDL-C为(1.83±0.52)mmol/L,各项数据优于对照组(t=13.148,P=0.000;t=17.483,P=0.000;t=3.260,P=0.000;t=15.030,P=0.000;t=11.190,P=0.000;t=8.457,P=0.000;t=8.582,P=0.000);研究组患者再次血运重建发生率为3.33%(1例),未见冠脉支架内再狭窄,心肌梗死的发生率为3.33%(1例),各项数据与对照组比较差异有统计学意义(χ~2=4.043,P=0.044;χ~2=4.286,P=0.038;χ~2=5.192,P=0.023)。结论新一代药物洗脱支架治疗冠脉支架内再狭窄可以改善患者躯体脂代谢情况,维持患者血压稳定,同时减少各类不良事件的发生率,预后疗效比较理想,优于药物涂层球囊治疗,建议在临床中推广。

Objective To compare the clinical efficacy of drug-coated balloon and new generation drug-eluting stent in the treatment of in-stent restenosis. Methods convenient select 60 patients with in-stent restenosis in the hospital were enrolled in this study. The patients were enrolled from February 2018 to June 2019. The patients were divided into two groups by digital random method. One group was treated with drug-coated balloon, the other group was treated with new generation drug-eluting stent, and the other group was treated with new generation drug-eluting stent as control group and the other group was treated with new generation drug-eluting stent. In the study group, lipid metabolism, incidence of adverse events and restenosis, and treatment satisfaction were compared between the two groups. Results After intervention in the study group, BMI was(20.31±1.31)kg/m^2, SBP was(122.31±4.22)mmHg, DBP was(87.83±4.22)mmHg, TC was(3.42±0.33)mmol/L, and TG was(1.56±0.62) mmol/L, HDL-C is(1.81±0.28)mmol/L, and LDL-C is(1.83±0.52)mmol/L. The data are better than the control group(t=13.148, P=0.000;t=17.483, P=0.000;t=3.260, P=0.000;t=15.030, P=0.000;t=11.190, P=0.000;t =8.457, P =0.000;t =8.582, P =0.000);the incidence of revascularization in the study group was 3.33%(1 case), no coronary restenosis was found, and the incidence of myocardial infarction was 3.33%(1 case). There was a statistical difference between the data and the control group(χ~2=4.043, P=0.044;χ~2=4.286, P=0.038;χ~2=5.192, P=0.023). Conclusion New generation drug-eluting stents can improve body fat metabolism, maintain blood pressure stability and reduce the incidence of adverse events. The prognosis is better than drug-coated balloon therapy. It is suggested that drug-eluting stents be popularized in clinical practice.